MCM
ROIV icon

Monimus Capital Management’s Roivant Sciences ROIV Stock Holding History

Monimus Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-137,058
Closed -$1.62M – 63
2024
Q4 		$1.62M Buy
+137,058
New +$1.62M 1.53% 25

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Monimus Capital Management's ROIV Position: Q1 2025 in Review

Monimus Capital Management sold out of Roivant Sciences (ROIV) in Q1 2025, closing a stake of 137,058 shares — an estimated $1.62M sold.

Monimus Capital Management first reported a position in ROIV in Q4 2024 and held it in 1 quarter. The position peaked at $1.62M in Q4 2024. 312 funds tracked by Wall St. Rank hold ROIV as of Q1 2025.

  • Monimus Capital Management reported no remaining Roivant Sciences position as of Q1 2025 after selling out during the quarter.
  • Monimus Capital Management sold 137,058 Roivant Sciences shares in Q1 2025, an estimated $1.62M.
  • Monimus Capital Management first reported a position in Roivant Sciences in Q4 2024 and held it in 1 quarter.
  • Monimus Capital Management's Roivant Sciences position peaked at $1.62M in Q4 2024.
  • 312 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2025.

Based on Monimus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.